Mediclinic International PLC (LON:MDC) had its price target decreased by research analysts at Jefferies Group from GBX 833 ($10.87) to GBX 812 ($10.60) in a research report issued to clients and investors on Wednesday. The firm presently has a “hold” rating on the stock. Jefferies Group’s target price indicates a potential downside of 13.11% from the stock’s current price.
A number of other research analysts have also recently weighed in on MDC. Citigroup Inc. raised Mediclinic International PLC to a “buy” rating and lifted their price objective for the company from GBX 990 ($12.92) to GBX 1,150 ($15.01) in a research report on Tuesday, June 28th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a GBX 1,160 ($15.14) price objective on shares of Mediclinic International PLC in a research report on Tuesday, August 23rd. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Mediclinic International PLC has an average rating of “Hold” and a consensus target price of GBX 964.43 ($12.59).
Shares of Mediclinic International PLC (LON:MDC) opened at 918.00 on Wednesday. The stock’s 50 day moving average price is GBX 1,006.76 and its 200-day moving average price is GBX 961.39. Mediclinic International PLC has a 1-year low of GBX 794.50 and a 1-year high of GBX 1,219.00. The stock’s market cap is GBX 6.77 billion.
Mediclinic International PLC Company Profile
Mediclinic International plc, formerly Al Noor Hospitals Group plc, is a holding company. The Company operates as an international private healthcare provider. Its segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services.
Receive News & Ratings for Mediclinic International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International PLC and related companies with MarketBeat.com's FREE daily email newsletter.